Neutrophils in antibody-based immunotherapy of cancer

Bibliography

• Dalgleish A, Pandha H. Tumour antigens as surrogate markers and targets for therapy and vaccines. Adv Cancer Res 2007;96:175-90
   PubMed Web of Science ®Google Scholar
• Malyankar UM. Tumour-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 2007;26(3-4):223-47
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-63
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23(9):1073-8
   PubMed Web of Science ®Google Scholar
• Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6(5):349-56
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Top Med Chem 2006;6(16):1657-86
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39-51
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43
   PubMed Web of Science ®Google Scholar
• Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25(3):158-64
   PubMed Web of Science ®Google Scholar
• Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95(2):652-6
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21(21):3940-7
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19(2):239-45
   PubMed Web of Science ®Google Scholar
• Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199(12):1659-69
   PubMed Web of Science ®Google Scholar
• Dyall R, Vasovic LV, Clynes RA, Nikolic-Zugic J. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumour. Eur J Immunol 1999;29(1):30-7
   PubMed Web of Science ®Google Scholar
• Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97(2):339-45
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992;327(2):28-35
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992;327(2):99-106
   PubMed Web of Science ®Google Scholar
• Midorikawa Y, Yamashita T, Sendo F. Modulation of the immune response to transplanted tumours in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumours by selective depletion of neutrophils in vivo. Cancer Res 1990;50(19):6243-7
   PubMed Web of Science ®Google Scholar
• Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66(16):8250-7
   PubMed Web of Science ®Google Scholar
• Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173(4):889-97
   PubMed Web of Science ®Google Scholar
• Dallegri F, Ottonello L, Ballestrero A, et al. Tumour cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation 1991;15(1):15-30
   PubMed Web of Science ®Google Scholar
• Clark RA, Klebanoff SJ. Neutrophil-mediated tumour cell cytotoxicity: role of the peroxidase system. J Exp Med 1975;141(6):1442-7
   PubMed Web of Science ®Google Scholar
• Clark RA, Olsson I, Klebanoff SJ. Cytotoxicity for tumour cells of cationic proteins from human neutrophil granules. J Cell Biol 1976;70(3):719-23
   PubMed Web of Science ®Google Scholar
• Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest 1991;88(1):93-100
   PubMed Web of Science ®Google Scholar
• Lichtenstein AK, Ganz T, Selsted ME, Lehrer RI. Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol 1988;114(1):104-16
   PubMed Web of Science ®Google Scholar
• Wagner C, Iking-Konert C, Denefleh B, Stegmaier S, Hug F, Hansch GM. Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils. Blood 2004;103(3):1099-104
   PubMed Web of Science ®Google Scholar
• Hochegger K, Eller P, Rosenkranz AR. Granzyme A: an additional weapon of human polymorphonuclear neutrophils (PMNs) in innate immunity? Blood 2004;103(3):1176
   PubMed Web of Science ®Google Scholar
• Grossman WJ, Ley TJ. Granzymes A and B are not expressed in human neutrophils. Blood 2004;104(3):906-7
   PubMed Web of Science ®Google Scholar
• Metkar SS, Froelich CJ. Human neutrophils lack granzyme A, granzyme B, and perforin. Blood 2004;104(3):905-6
   PubMed Web of Science ®Google Scholar
• Musiani P, Allione A, Modica A, et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest 1996;74(1):146-57
   PubMed Web of Science ®Google Scholar
• Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med 1991;173(3):771-4
   PubMed Web of Science ®Google Scholar
• Gasperini S, Calzetti F, Russo MP, De Gironcoli M, Cassatella MA. Regulation of GRO alpha production in human granulocytes. J Inflamm 1995;45(3):143-51
   PubMedGoogle Scholar
• Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996;97(8):1931-41
   PubMed Web of Science ®Google Scholar
• Burn TC, Petrovick MS, Hohaus S, Rollins BJ, Tenen DG. Monocyte chemoattractant protein-1 gene is expressed in activated neutrophils and retinoic acid-induced human myeloid cell lines. Blood 1994;84(8):2776-83
   PubMed Web of Science ®Google Scholar
• Kasama T, Strieter RM, Standiford TJ, Burdick MD, Kunkel SL. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J Exp Med 1993;178(1):63-72
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leuk Biol 2000;68(1):9-14
   PubMed Web of Science ®Google Scholar
• Tani K, Murphy WJ, Chertov O, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000;12(5):691-700
   PubMed Web of Science ®Google Scholar
• Oehler L, Majdic O, Pickl WF, et al. Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J Exp Med 1998;187(7):1019-28
   PubMed Web of Science ®Google Scholar
• Iking-Konert C, Cseko C, Wagner C, Stegmaier S, Andrassy K, Hansch GM. Transdifferentiation of polymorphonuclear neutrophils: acquisition of CD83 and other functional characteristics of dendritic cells. J Mol Med 2001;79(8):464-74
   PubMed Web of Science ®Google Scholar
• Iking-Konert C, Ostendorf B, Sander O, et al. Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. Ann Rheum Dis 2005;64(10):1436-42
   PubMed Web of Science ®Google Scholar
• Van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, Van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 2005;201(8):1281-92
   PubMed Web of Science ®Google Scholar
• Ludwig IS, Geijtenbeek TB, Van Kooyk Y. Two way communication between neutrophils and dendritic cells. Curr Opin Pharmacol 2006;6(4):408-13
   PubMed Web of Science ®Google Scholar
• Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003;171(11):6052-8
   PubMed Web of Science ®Google Scholar
• Van Gisbergen KP, Geijtenbeek TB, Van Kooyk Y. Close encounters of neutrophils and DCs. Trends Immunol 2005;26(12):626-31
   PubMed Web of Science ®Google Scholar
• Megiovanni AM, Sanchez F, Robledo-Sarmiento M, Morel C, Gluckman JC, Boudaly S. Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. J Leuk Biol 2006;79(5):977-88
   PubMed Web of Science ®Google Scholar
• Gale RP, Zighelboim J. Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J Immunol 1975;114(3):1047-51
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90
   PubMed Web of Science ®Google Scholar
• Valerius T, Wurflein D, Stockmeyer B, Repp R, Kalden JR, Gramatzki M. Activated neutrophils as effector cells for bispecific antibodies. Cancer Immunol Immunother 1997;45(3-4):142-5
   PubMed Web of Science ®Google Scholar
• Ottonello L, Epstein AL, Mancini M, Dapino P, Dallegri F. Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. J Leuk Biol 2004;75(1):99-105
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19(22):4189-94
   PubMed Web of Science ®Google Scholar
• Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24(18):2885-90
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung NK. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumour cells by polymorphonuclear leukocytes. Cancer Res 1991;51(18):4865-70
   PubMed Web of Science ®Google Scholar
• Repp R, Valerius T, Sendler A, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78(4):885-9
   PubMed Web of Science ®Google Scholar
• Valerius T, Repp R, De Wit TP, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI;CD64) in enhanced tumour cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993;82(3):931-9
   PubMed Web of Science ®Google Scholar
• Van Der Kolk LE, Grillo-Lopez AJ, Baars JW, Van Oers MH. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003;17(8):1658-64
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hayama M, Okamoto M, et al. Phase I study of rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res 2004;10(12 Pt 1):4077-82
   PubMed Web of Science ®Google Scholar
• Van Spriel AB, Van Ojik HH, Van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000;21(8):391-7
   PubMedGoogle Scholar
• Wurflein D, Dechant M, Stockmeyer B, et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998;58(14):3051-8
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Valerius T, Repp R, et al. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997;57(4):696-701
   PubMed Web of Science ®Google Scholar
• Elsasser D, Valerius T, Repp R, Weiner GJ, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996;87(9):3803-12
   PubMed Web of Science ®Google Scholar
• Schweizer C, Strauss G, Lindner M, Marme A, Deo YM, Moldenhauer G. Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAMxCD64 (HEA125x197) bispecific antibody. Cancer Immunol Immunother 2002;51(11-12):621-9
   PubMed Web of Science ®Google Scholar
• Keler T, Graziano RF, Mandal A, et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumour cells by Fc gamma receptor type I-expressing effector cells. Cancer Res 1997;57(18):4008-14
   PubMed Web of Science ®Google Scholar
• Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997;45(3-4):210-15
   PubMed Web of Science ®Google Scholar
• Chen J, Mokotoff M, Zhou JH, Fanger MW, Ball ED. An immunoconjugate of Lys3-bombesin and monoclonal antibody 22 can specifically induce FcgammaRI (CD64)-dependent monocyte- and neutrophil-mediated lysis of small cell carcinoma of the lung cells. Clin Cancer Res 1995;1(4):425-34
   PubMed Web of Science ®Google Scholar
• Heijnen IA, Van Vugt MJ, Fanger NA, et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 1996;97(2):331-8
   PubMed Web of Science ®Google Scholar
• Heijnen IA, Rijks LJ, Schiel A, et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. J Immunol 1997;159(11):5629-39
   PubMed Web of Science ®Google Scholar
• Van Ojik HH, Bevaart L, Dahle CE, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003;63(17):5595-600
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000;96(10):3544-52
   PubMed Web of Science ®Google Scholar
• Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13(9):2281-92
   PubMed Web of Science ®Google Scholar
• Schwaab T, Lewis LD, Cole BF, et al. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI × anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 2001;24(1):79-87
   PubMed Web of Science ®Google Scholar
• Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A Phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumours. Cancer Immunol Immunother 2007;57(2):155-63
   PubMed Web of Science ®Google Scholar
• Posey JA, Raspet R, Verma U, et al. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 1999;22(4):371-9
   PubMed Web of Science ®Google Scholar
• James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT. A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 2001;85(2):152-6
   PubMed Web of Science ®Google Scholar
• Lewis LD, Cole BF, Wallace PK, et al. Pharmacokinetic–pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 2001;248(1-2):149-65
   PubMed Web of Science ®Google Scholar
• Lewis LD, Beelen AP, Cole BF, et al. The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother Pharmacol 2002;49(5):375-84
   PubMed Web of Science ®Google Scholar
• Repp R, Valerius T, Wieland G, et al. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcgammaRI and to HER-2/neu (MDX-210). J Hematother 1995;4(5):415-21
   PubMedGoogle Scholar
• Van Ojik HH, Repp R, Groenewegen G, Valerius T, Van De Winkel JG. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother 1997;45(3-4):207-9
   PubMed Web of Science ®Google Scholar
• Repp R, Van Ojik HH, Valerius T, et al. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI × anti-HER-2/neu) in combination with filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003;89(12):2234-43
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Deo Y, Link J, et al. A Phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother 1999;48(1):9-21
   PubMed Web of Science ®Google Scholar
• Otten MA, Rudolph E, Dechant M, et al. Immature neutrophils mediate tumour cell killing via IgA but not IgG Fc receptors. J Immunol 2005;174(9):5472-80
   PubMed Web of Science ®Google Scholar
• Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 1991;77(10):2154-9
   PubMed Web of Science ®Google Scholar
• Bevaart L, Jansen MJ, Van Vugt MJ, Verbeek JS, Van De Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006;66(3):1261-4
   PubMed Web of Science ®Google Scholar
• Tan PS, Gavin AL, Barnes N, et al. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 2003;170(5):2549-56
   PubMed Web of Science ®Google Scholar
• Valerius T, Stockmeyer B, Van Spriel AB, et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997;90(11):4485-92
   PubMed Web of Science ®Google Scholar
• Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumour antigens efficiently promote cell-mediated cytotoxicity of tumour targets in whole blood. J Immunol 1998;160(4):1677-86
   PubMed Web of Science ®Google Scholar
• Monteiro RC, Kubagawa H, Cooper MD. Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 1990;171(3):597-613
   PubMed Web of Science ®Google Scholar
• Shen L. Receptors for IgA on phagocytic cells. Immunol Res 1992;11(3-4):273-82
   PubMed Web of Science ®Google Scholar
• Van Egmond M, Van Garderen E, Van Spriel AB, et al. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000;6(6):680-5
   PubMed Web of Science ®Google Scholar
• Pasquier B, Launay P, Kanamaru Y, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22(1):31-42
   PubMed Web of Science ®Google Scholar
• Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204
   PubMed Web of Science ®Google Scholar
• Van Egmond M, Damen CA, Van Spriel AB, Vidarsson G, Van Garderen E, Van De Winkel JG. IgA and the IgA Fc receptor. Trends Immunol 2001;22(4):205-11
   PubMed Web of Science ®Google Scholar
• Huls G, Heijnen IA, Cuomo E, et al. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 1999;59(22):5778-84
   PubMed Web of Science ®Google Scholar
• Stadick H, Stockmeyer B, Kuhn R, et al. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? J Urol 2002;167(2 Pt 1):707-12
   PubMed Web of Science ®Google Scholar
• Sundarapandiyan K, Keler T, Behnke D, et al. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J Immunol Methods 2001;248(1-2):113-23
   PubMed Web of Science ®Google Scholar
• Elsasser D, Stadick H, Stark S, et al. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res 1999;19(2C):1525-8
   PubMed Web of Science ®Google Scholar
• Dechant M, Vidarsson G, Stockmeyer B, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002;100(13):4574-80
   PubMed Web of Science ®Google Scholar
• Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 2001;39(1-2):69-77
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Dechant M, Van Egmond M, et al. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000;165(10):5954-61
   PubMed Web of Science ®Google Scholar
• Ernst LK, Duchemin AM, Anderson CL. Association of the high-affinity receptor for IgG (Fc gamma RI) with the gamma subunit of the IgE receptor. Proc Natl Acad Sci USA 1993;90(13):6023-7
   PubMed Web of Science ®Google Scholar
• Pfefferkorn LC, Yeaman GR. Association of IgA-Fc receptors (Fc alpha R) with Fc epsilon RI gamma 2 subunits in U937 cells. Aggregation induces the tyrosine phosphorylation of gamma 2. J Immunol 1994;153(7):3228-36
   PubMed Web of Science ®Google Scholar
• Van Egmond M, Van Vuuren AJ, Morton HC, et al. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999;93(12):4387-94
   PubMed Web of Science ®Google Scholar
• Van Vugt MJ, Heijnen AF, Capel PJ, et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood 1996;87(9):3593-9
   PubMed Web of Science ®Google Scholar
• Morton HC, Van Den Herik-Oudijk IE, Vossebeld P, et al. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. J Biol Chem 1995;270(50):29781-7
   PubMed Web of Science ®Google Scholar
• Otten MA, Leusen JH, Rudolph E, et al. FcR {gamma}-chain dependent signalling in immature neutrophils is mediated by Fc{alpha}RI, but Not by Fc{gamma}RI. J Immunol 2007;179(5):2918-24
   PubMed Web of Science ®Google Scholar
• Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem 1999;274(11):7216-25
   PubMed Web of Science ®Google Scholar
• Horner H, Frank C, Dechant C, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007;179(1):337-45
   PubMed Web of Science ®Google Scholar
• Van Spriel AB, Leusen JH, Van Egmond M, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001;97(8):2478-86
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Beyer T, Neuhuber W, et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003;171(10):5124-9
   PubMed Web of Science ®Google Scholar
• Hong F, Hansen RD, Yan J, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003;63(24):9023-31
   PubMed Web of Science ®Google Scholar
• Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumour models. J Immunol 2004;173(2):797-806
   PubMed Web of Science ®Google Scholar
• Allendorf DJ, Yan J, Ross GD, et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumour immunotherapy facilitated by anti-tumour monoclonal antibody and beta-glucan. J Immunol 2005;174(11):7050-6
   PubMed Web of Science ®Google Scholar
• Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer 1996;77(7):1226-43
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4(1):71-8
   PubMed Web of Science ®Google Scholar
• Dechant M, Beyer T, Schneider-Merck T, et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007;179(5):2936-43
   PubMed Web of Science ®Google Scholar